Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

644TiP - SAABR: Single arm phase II study of abiraterone + atezolizumab + GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Prostate Cancer

Presenters

Dana Rathkopf

Citation

Annals of Oncology (2021) 32 (suppl_5): S626-S677. 10.1016/annonc/annonc702

Authors

D.E. Rathkopf1, B. Decker1, P. Schum2, S. McBride3

Author affiliations

  • 1 Department Of Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2 Nursing, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 3 Department Of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 644TiP

Background

Several phase III trials have demonstrated that adding the androgen synthesis inhibitor abiraterone acetate (AA) to androgen deprivation therapy (ADT) offers a survival benefit for men with mHSPC. Moreover, 1) outcomes in subjects with locally advanced disease enrolled on STAMPEDE suggest that prostate radiation therapy may be associated with a reduction in treatment failure and 2) preclinical studies have shown that SBRT can induce an immunogenic effect through enhanced expression of the PD-L1 protein on tumor and immune cells. Therefore, combining androgen ablation (AA + ADT) with the cytotoxic and immune properties of SBRT and the additional effects of atezolizumab (ATEZO), an anti-PD-L1 immunotherapy, could be a new treatment approach with potential synergistic effects.

Trial design

The primary objective is to evaluate the failure-free rate at 2 years (binary endpoint). Failure is defined as biochemical failure; radiographic progression (as defined by PCWG3); or death from any cause. ATEZO will be administered to men with newly diagnosed mHSPC by IV infusion (1200 mg IV over 60 minutes every 3 weeks) followed after Cycle 1 by AA (1000 mg PO every day with prednisone 5 mg daily), ADT (GnRH analog), and SBRT (7.25-7.50 Gy x 5 fractions to prostate and seminal vesicles every other day starting at Cycle 5 Day 1 ± 5 days) until unacceptable toxicity, protocol defined progression, or 2 years of treatment. ATEZO will be continued for a maximum of 2 years. Continuation of AA and ADT beyond 2 years is at the discretion of the treating physician per local standard of care. For the first 20 patients, a biopsy will be done after initiation of ATEZO but before AA; for the final 22 patients, biopsy will be done while on both ATEZO and AA, but before SBRT. Biopsy results at diagnosis and on treatment will be compared for correlative analyses. Up to 10 subjects who initiated treatment on GnRH analog prior to treatment consent will be enrolled. 10 of the planned 42 evaluable subjects have been enrolled. PCCTC-managed; Genentech-funded.

Clinical trial identification

NCT04262154.

Editorial acknowledgement

Legal entity responsible for the study

Memorial Sloan Kettering Cancer Center.

Funding

Stand Up to Cancer and Genentech.

Disclosure

D.E. Rathkopf: Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: Genentech; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: Myovant Sciences; Financial Interests, Personal and Institutional, Funding: Janssen Oncology; Financial Interests, Personal and Institutional, Funding: Medivation; Financial Interests, Personal and Institutional, Funding: Celgene; Financial Interests, Personal and Institutional, Funding: Takeda; Financial Interests, Personal and Institutional, Funding: Millennium; Financial Interests, Personal and Institutional, Funding: Ferring; Financial Interests, Personal and Institutional, Funding: Novartis; Financial Interests, Personal and Institutional, Funding: Taiho Pharmaceutical; Financial Interests, Personal and Institutional, Funding: AstraZeneca; Financial Interests, Personal and Institutional, Funding: Genentech/Roche; Financial Interests, Personal and Institutional, Funding: Tracon Pharma; Financial Interests, Personal and Institutional, Funding: Bayer; Financial Interests, Personal and Institutional, Funding: Phosplatin Therapeutics. S. McBride: Financial Interests, Personal and Institutional, Funding: Genentech; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.